{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Califano D"],"funding":["University of Campania \"Luigi Vanvitelli\"","Ministero della Salute","Ministero degli Affari Esteri","University of Campania &quot;Luigi Vanvitelli&quot;","Italian Association for Cancer Research","Associazione Italiana Di Oncologia Medica"],"pagination":["5152"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8533892"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(20)"],"pubmed_abstract":["<h4>Background</h4>Epithelial ovarian cancer (EOC) is a rare, highly lethal disease. In a subset of high grade EOC patients, maintenance therapy with the antiangiogenic drug Bevacizumab (BEV) is a valuable option. To date, no validated predictive or prognostic biomarkers exist for selecting EOC patients that might benefit from BEV treatment.<h4>Methods</h4>Immunohistochemistry and RT-qPCR evaluated the expression of seven angiogenesis-related proteins and of a twelve microRNAs angio-signature in EOC patients, treated in first line with chemotherapy plus BEV (MITO16A/ManGO OV-2 phase IV trial). Centralized statistical analyses assessed the associations between each biomarker, clinical prognostic factors and survival outcomes.<h4>Results</h4>High miR-484 expression was associated with longer"],"journal":["Cancers"],"pubmed_title":["Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study."],"pmcid":["PMC8533892"],"funding_grant_id":["To S.P.","CRO Ricerca Corrente grant (linea 1)","RCR-2019-23669115","PGR01230","IRCCS-G. Pascale Ricerca Corrente grant M2/7","Programma VALERE","20902","RF-2016-02361040"],"pubmed_authors":["Russo D","Citron F","Perrone F","Montella M","Bignotti E","Gargiulo P","Zannoni GF","Signoriello S","Chiodini P","Simeon V","Scambia G","Losito NS","Baldassarre G","Scognamiglio G","Gallo D","De Cecio R","Spina A","Canzonieri V","Rampioni Vinciguerra GL","Pignata S","Cecere SC","Schettino C","Ferrandina G","Piccirillo MC","Tognon G","Del Sesto M","Califano D","Arenare L","Colombo N","Ciucci A"],"additional_accession":[]},"is_claimable":false,"name":"Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study.","description":"<h4>Background</h4>Epithelial ovarian cancer (EOC) is a rare, highly lethal disease. In a subset of high grade EOC patients, maintenance therapy with the antiangiogenic drug Bevacizumab (BEV) is a valuable option. To date, no validated predictive or prognostic biomarkers exist for selecting EOC patients that might benefit from BEV treatment.<h4>Methods</h4>Immunohistochemistry and RT-qPCR evaluated the expression of seven angiogenesis-related proteins and of a twelve microRNAs angio-signature in EOC patients, treated in first line with chemotherapy plus BEV (MITO16A/ManGO OV-2 phase IV trial). Centralized statistical analyses assessed the associations between each biomarker, clinical prognostic factors and survival outcomes.<h4>Results</h4>High miR-484 expression was associated with longer","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2026-04-08T06:49:01.614Z","creation":"2025-02-19T03:53:15.16Z"},"accession":"S-EPMC8533892","cross_references":{"pubmed":["34680301"],"doi":["10.3390/cancers13205152"]}}